Ceapro Inc. (CZO.V)
| Previous Close | 0.3600 |
| Open | 0.3500 |
| Bid | 0.3850 x 0 |
| Ask | 0.4000 x 0 |
| Day's Range | 0.3400 - 0.4000 |
| 52 Week Range | 0.3400 - 0.8200 |
| Volume | |
| Avg. Volume | 39,873 |
| Market Cap | 31.317M |
| Beta (5Y Monthly) | 1.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | Nov 07, 2023 - Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireCeapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization - Ended the quarter with $11.3 million in cash allowing funding for planned pipeline and technology developments - Ongoing strategic corporate discussions progressing and continued planning for uplisting to Nasdaq EDMONTON, Alberta, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: C
- GlobeNewswire
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
– Exclusive agreement extended from 3 to 5 years until December 31, 2026 – Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market – Offering of new preservative free dry product formulation for oat beta glucan EDMONTON, Alberta, Aug. 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization o
- GlobeNewswire
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
– New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products – EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the expansion of its collaboration with the Angiogenesis Foundation to conduct re
